Pfizer’s COVID-19 vaccine is 100 p.c effective in kids aged 12 to 15, the corporate mentioned Wednesday — elevating hopes that adolescents may begin getting the jab earlier than the following faculty 12 months.
The groundbreaking shot generated “strong” immune responses to the lethal coronavirus amongst that age group that outpaced the response recorded in 16-to-25-year-olds, the Manhattan-based drugmaker mentioned.
Pfizer and its German associate, BioNTech, drew these conclusions from a medical trial of their vaccine in 2,260 US adolescents. Some 18 individuals got here down with COVID-19 after getting a placebo however not one of the 1,131 kids who obtained the vaccine contracted the virus, the companies mentioned.
The shot was additionally “properly tolerated” amongst 12-to-15-year-olds and generated negative effects “typically constant” with these seen in older teenagers and young adults, in response to the businesses.
Pfizer and BioNTech plan to submit the brand new information to drug regulators in the US and Europe “with the hope of beginning to vaccinate this age group earlier than the beginning of the following faculty 12 months,” in response to Pfizer CEO Albert Bourla.
“It is essential to allow them to get again to on a regular basis faculty life and to satisfy family and friends whereas defending them and their family members,” BioNTech CEO Ugur Sahin mentioned in a press release.
Whereas the information haven’t been peer-reviewed, Pfizer and BioNTech hope the US Meals and Drug Administration and the European Medicines Company will amend their emergency approvals for the vaccine so it may be distributed to adolescents as quickly as potential. Each regulators have solely cleared the shot to be used in folks 16 and older.
Pfizer and BioNTech have additionally began finding out the vaccine in youngsters between 6 months and 11 years outdated. Kids aged 5 to 11 in the examine obtained their first doses final week and dosing will begin in the 2-to-5-year-old cohort will start subsequent week, the businesses mentioned.
Pfizer shares climbed about 0.6 p.c to $36.32 in premarket buying and selling as of seven:54 a.m.